The first successful experience of high-dose chemotherapy following autologous hematopoietic stem cell transplantation for Hodgkin lymphoma in a patient with hiv infection at the pirogov national medical and surgical center

The risk of developing Hodgkin Lymphoma (HL) is 5 to 26 times higher in HIV-infected patients compared to the general population. HL can develop even with moderate immune suppression and treatment with antiretroviral medicines. This article reviews the current treatment strategy for HL in HIV-infected patients and describes the first successful experience of high-dose chemotherapy following autologous hematopoietic stem cell transplantation (autoHSCT) in an HIV-infected patient at the Hematology Department of the Pirogov National Medical and Surgical Center. This clinical case demonstrates the efficacy and safety of autoHSCT for treatment of relapsed and refractory HL in patients with HIV infection.